Loading...

Johnson & Johnson 1-dose Shot Prevents COVID-19, But Less Than Some Others

January 29, 2021by Lauran Neergaard and Linda A. Johnson, Associated Press
This Sept. 2020 photo provided by Johnson & Johnson shows the investigational Janssen COVID-19 vaccine. Johnson & Johnson's long-awaited COVID-19 vaccine appears to protect against symptomatic illness with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. Johnson & Johnson said Friday, Jan. 29, 2021 that in the U.S. and seven other countries, the first single-shot vaccine appears 66% effective overall at preventing moderate to severe COVID-19. It was more protective against severe symptoms, 85%. (Cheryl Gerber/Johnson & Johnson via AP)

Johnson & Johnson’s long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses.

J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms.

There was some geographic variation. The vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus.

“Gambling on one dose was certainly worthwhile,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press.

With vaccinations off to a rocky start globally, experts had been counting on a one-dose vaccine that would stretch scarce supplies and avoid the logistics nightmare of getting people to return for boosters.

But with some other competing vaccines shown to be 95% effective after two doses, at question is whether somewhat less protection is an acceptable tradeoff to get more shots in arms quickly.

The company said within a week, it will file an application for emergency use in the U.S., and then abroad. It expects to supply 100 million doses to the U.S. by June, and expects to have some ready to ship as soon as authorities give the green light.

These are preliminary findings from a study of 44,000 volunteers that isn’t completed yet. Researchers tracked illnesses starting 28 days after vaccination – about the time when, if participants were getting a two-dose variety instead, they would have needed another shot.

After day 28, no one who got vaccinated needed hospitalization or died regardless of whether they were exposed to “regular COVID or these particularly nasty variants,” Mammen said. When the vaccinated did become infected, they had a milder illness.

Defeating the scourge that has killed more than 2 million people worldwide will require vaccinating billions, and the shots being rolled out in different countries so far all require two doses a few weeks apart for full protection. Early data is mixed on exactly how well all the different kinds work, but shots made by Pfizer and Moderna appear to be about 95% protective after the second dose.

But amid shortages, some countries have advised delaying the second dose of certain vaccines with little data on how that would affect protection.

All COVID-19 vaccines train the body to recognize the new coronavirus, usually by spotting the spikey protein that coats it. But they’re made in very different ways.

J&J’s shot uses a cold virus like a Trojan horse to carry the spike gene into the body, where cells make harmless copies of the protein to prime the immune system in case the real virus comes along.

Rival AstraZeneca makes a similar cold virus vaccine that requires two doses. Both the AstraZeneca and J&J vaccines can be stored in a refrigerator, making them easier to ship and to use in developing countries than the frozen kind made by Pfizer and Moderna.

It’s not clear exactly how well the AstraZeneca version, being used in Britain and several other countries, works. Tests in Britain, South Africa and Brazil suggested two doses are about 70% effective although there are questions about how much protection older adults get. An ongoing U.S. study may provide more information.

J&J said its vaccine works consistently in a broad range of people: A third of participants were over age 60, and more than 40% had other illnesses putting them at risk of severe COVID-19, including obesity, diabetes and HIV.

J&J said the vaccine is safe, with reactions similar to other COVID-19 shots such as fever that occur when the immune system is revved up.

While it released few details, the company said there were no serious allergic reactions. But occasionally other COVID-19 vaccines trigger such reactions, which can be reversed if promptly treated – and authorities have warned people to be on the lookout regardless of which type of vaccine is used.

J&J had hedged its bets with a study of a two-dose version of its vaccine, which is still underway.

Friday’s interim results come on the heels of another vaccine in final testing. Novavax reported this week that its vaccine appears 89% effective in a U.K. study and that it also seems to work — though not as well — against new mutated versions of the virus circulating in Britain and South Africa. A larger study in the U.S. and Mexico is still enrolling volunteers.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Health

November 29, 2021
by Dan McCue
Biden Tells Americans New COVID Variant ‘Not Cause for Panic’

WASHINGTON — President Joe Biden addressed the nation Monday, calling the new omicron variant of the coronavirus a cause for... Read More

WASHINGTON — President Joe Biden addressed the nation Monday, calling the new omicron variant of the coronavirus a cause for concern “but not a cause for panic.” Speaking in the Roosevelt Room of the White House, as Dr. Anthony Fauci, director of the National Institute of... Read More

Biden Pushes Shots, Not More Restrictions as Variant Spreads

WASHINGTON (AP) — President Joe Biden will urge Americans to get vaccinated and to receive a booster shot as he... Read More

WASHINGTON (AP) — President Joe Biden will urge Americans to get vaccinated and to receive a booster shot as he seeks to quell concerns Monday over the new COVID-19 variant omicron, but won't immediately push for more restrictions to stop its spread, his chief medical adviser said.... Read More

Supreme Court Set to Take Up All-or-Nothing Abortion Fight

WASHINGTON (AP) — Both sides are telling the Supreme Court there's no middle ground in Wednesday's showdown over abortion. The justices can... Read More

WASHINGTON (AP) — Both sides are telling the Supreme Court there's no middle ground in Wednesday's showdown over abortion. The justices can either reaffirm the constitutional right to an abortion or wipe it away altogether. Roe v. Wade, the landmark 1973 ruling that declared a nationwide right to abortion, is... Read More

Fauci Fires Back at Cruz Over COVID Claims About Chinese Lab

WASHINGTON (AP) — Dr. Anthony Fauci, the government’s top infectious diseases expert, blasted Sen. Ted Cruz for suggesting that Fauci... Read More

WASHINGTON (AP) — Dr. Anthony Fauci, the government’s top infectious diseases expert, blasted Sen. Ted Cruz for suggesting that Fauci be investigated for statements he made about COVID-19 and said the criticism by the Texas Republican was an attack on science. “I should be prosecuted? What happened on... Read More

November 26, 2021
by Dan McCue
US Restricts Travel From 8 Countries in Response to Omicron Variant

WASHINGTON - The Biden Administration on Friday imposed air travel restrictions on eight African nations in response to a new... Read More

WASHINGTON - The Biden Administration on Friday imposed air travel restrictions on eight African nations in response to a new COVID strain first detected in South Africa. The new travel restrictions, which go into effect Monday, apply to citizens of South Africa, Botswana, Zimbabwe, Namibia, Lesotho,... Read More

World Takes Action as New Variant Emerges in Southern Africa

BRUSSELS (AP) — A slew of nations moved to stop air travel from southern Africa on Friday, and stocks plunged... Read More

BRUSSELS (AP) — A slew of nations moved to stop air travel from southern Africa on Friday, and stocks plunged in Asia and Europe in reaction to news of a new, potentially more transmissible COVID-19 variant. "The last thing we need is to bring in a... Read More

News From The Well
Exit mobile version